Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma

• Published in: Molecular cancer therapeutics 2021-10, Vol.20 (10), p.1868-1879
• Main Authors: Heisey, Daniel A R, Jacob, Sheeba, Lochmann, Timothy L, Kurupi, Richard, Ghotra, Maninderjit S, Calbert, Marissa L, Shende, Mayuri, Maves, Yuki Kato, Koblinski, Jennifer E, Dozmorov, Mikhail G, Boikos, Sosipatros A, Benes, Cyril H, Faber, Anthony C
• Format: Article
• Language: English
• Subjects: Animals; Apoptosis; Benzazepines - pharmacology; Bone Neoplasms - drug therapy; Bone Neoplasms - genetics; Bone Neoplasms - pathology; Cell Proliferation; DNA-Directed RNA Polymerases - antagonists & inhibitors; Gene Expression Regulation, Neoplastic; Histones - antagonists & inhibitors; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Oncogene Proteins, Fusion - antagonists & inhibitors; Phenylenediamines - pharmacology; Proto-Oncogene Protein c-fli-1 - antagonists & inhibitors; Pyrimidines - pharmacology; RNA-Binding Protein EWS - antagonists & inhibitors; Sarcoma, Ewing - drug therapy; Sarcoma, Ewing - genetics; Sarcoma, Ewing - pathology; Transcriptome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays
• ISSN: 1535-7163; 1538-8514
• DOI: 10.1158/1535-7163.MCT-20-0489

The translocation is the hallmark genomic alteration of Ewing sarcoma, a malignancy of the bone and surrounding tissue, predominantly affecting children and adolescents. Although significant progress has been made for the treatment of localized disease, patients with metastasis or who relapse after chemotherapy have less than a 30% five-year survival rate. EWS-FLI1 is currently not clinically druggable, driving the need for more effective targeted therapies. Treatment with the H3K27 demethylase inhibitor, GSK-J4, leads to an increase in H3K27me and a decrease in H3K27ac, a significant event in Ewing sarcoma because H3K27ac associates strongly with EWS-FLI1 binding at enhancers and promoters and subsequent activity of EWS-FLI1 target genes. We were able to identify targets of EWS-FLI1 tumorigenesis directly inhibited by GSK-J4. GSK-J4 disruption of EWS-FLI1-driven transcription was toxic to Ewing sarcoma cells and slowed tumor growth in patient-derived xenografts (PDX) of Ewing sarcoma. Responses were markedly exacerbated by cotreatment with a disruptor of RNA polymerase II activity, the CDK7 inhibitor THZ1. This combination together suppressed EWS-FLI1 target genes and viability of PDX Ewing sarcoma cells in a synergistic manner. In PDX models of Ewing Sarcoma, the combination shrank tumors. We present a new therapeutic strategy to treat Ewing sarcoma by decreasing H3K27ac at EWS-FLI1 driven transcripts, exacerbated by blocking phosphorylation of the C-terminal domain of RNA polymerase II to further hinder the EWS-FLI1-driven transcriptome.